Cycloastragenol: An exciting novel candidate for age‑associated diseases (Review)

Yu,Yongjie; Zhou,Limin; Yang,Yajun; Liu,Yuyu

doi:10.3892/etm.2018.6501

Cycloastragenol: An exciting novel candidate for age‑associated diseases (Review)

Authors:
- Yongjie Yu
- Limin Zhou
- Yajun Yang
- Yuyu Liu
View Affiliations

Affiliations: Department of Pharmacology, Guangdong Medical University, Zhanjiang, Guangdong 524023, P.R. China
Published online on: July 20, 2018 https://doi.org/10.3892/etm.2018.6501
Pages: 2175-2182
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cycloastragenol (CAG) is a triterpenoid saponin compound and a hydrolysis product of the main active ingredient in Astragalus membranaceus (Fisch.) Bunge. An increasing body of evidence has indicated that CAG has a wide spectrum of pharmacological functions, which are attracting attention in the research community. The aim of the present review paper was to review and elucidate the advanced study of CAG. The focus was on advanced studies of CAG in English and Chinese databases; the literature was collected and reviewed to summarize the latest efficacy, pharmacokinetics and adverse reactions of CAG. Extensive pharmacological effects have been attributed to CAG, including telomerase activation, telomere elongation, anti‑inflammatory and anti‑oxidative properties; CAG has also been reported to improve lipid metabolism. Clinical research has demonstrated that CAG activates telomerase in humans and ameliorates various biomarkers. CAG is absorbed through the intestinal epithelium via passive diffusion and undergoes first‑pass hepatic metabolism. Within a certain dose range, oral CAG is relatively safe; however, underlying mechanisms associated with CAG are not clear, and thus, we should be aware of potential adverse reactions associated with CAG. According to existing studies and clinical trials, CAG is safe and has broad application prospects. However, further studies are required to fully understand its efficacy and potential adverse reactions, and to ensure the proper use of CAG is applied to treat diseases clinically.

View Figures

View References

1	Shen CY, Jiang JG, Yang L, Wang DW and Zhu W: Anti-ageing active ingredients from herbs and nutraceuticals used in traditional Chinese medicine: Pharmacological mechanisms and implications for drug discovery. Br J Pharmacol. 174:1395–1425. 2017. View Article : Google Scholar : PubMed/NCBI
2	Zhang S, Lu J, Yan J and Zhang H: Research progress of preparation technology and pharmacological effect of cycloastragenol. Chin J New Drugs. 16:1872–1875. 2016.
3	Ip FC, Ng YP, An HJ, Dai Y, Pang HH, Hu YQ, Chin AC, Harley CB, Wong YH and Ip NY: Cycloastragenol is a potent telomerase activator in neuronal cells: Implications for depression management. Neurosignals. 22:52–63. 2014. View Article : Google Scholar : PubMed/NCBI
4	Salvador L, Singaravelu G, Harley CB, Flom P, Suram A and Raffaele JM: A natural product telomerase activator lengthens telomeres in humans: A randomized, double blind and placebo controlled study. Rejuvenation Res. 19:478–484. 2016. View Article : Google Scholar : PubMed/NCBI
5	Hemann MT, Strong MA, Hao LY and Greider CW: The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell. 107:67–77. 2001. View Article : Google Scholar : PubMed/NCBI
6	Bernardes de Jesus B, Schneeberger K, Vera E, Tejera A, Harley CB and Blasco MA: The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell. 10:604–621. 2011. View Article : Google Scholar : PubMed/NCBI
7	Le Saux CJ, Davy P, Brampton C, Ahuja SS, Fauce S, Shivshankar P, Nguyen H, Ramaseshan M, Tressler R, Pirot Z, et al: A novel telomerase activator suppresses lung damage in a murine model of idiopathic pulmonary fibrosis. PLoS One. 8:e584232013. View Article : Google Scholar : PubMed/NCBI
8	Yung LY, Lam WS, Ho MK, Hu Y, Ip FC, Pang H, Chin AC, Harley CB, Ip NY and Wong YH: Astragaloside IV and cycloastragenol stimulate the phosphorylation of extracellular signal-regulated protein kinase in multiple cell types. Planta Med. 78:115–121. 2012. View Article : Google Scholar : PubMed/NCBI
9	Li J: Astragaloside IV and cycloastragenol attenuate osteoblastic injury and aging elicited by oxidative stress. 2017.
10	Bektas A, Schurman SH, Sen R and Ferrucci L: Human T cell immunosenescence and inflammation in aging. J Leukoc Biol. 102:977–988. 2017. View Article : Google Scholar : PubMed/NCBI
11	Molgora B, Bateman R, Sweeney G, Finger D, Dimler T, Effros RB and Valenzuela HF: Functional assessment of pharmacological telomerase activators in human T cells. Cells. 2:57–66. 2013. View Article : Google Scholar : PubMed/NCBI
12	Verotta L, Guerrini M, El-Sebakhy NA, Assad AM, Toaima SM, Radwan MM, Luo YD and Pezzuto JM: Cycloartane and oleanane saponins from egyptian Astragalus spp. as modulators of lymphocyte proliferation. Planta Med. 68:986–994. 2002. View Article : Google Scholar : PubMed/NCBI
13	Fauce SR, Jamieson BD, Chin AC, Mitsuyasu RT, Parish ST, Ng HL, Kitchen CM, Yang OO, Harley CB and Effros RB: Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. J Immunol. 181:7400–7406. 2008. View Article : Google Scholar : PubMed/NCBI
14	Sevimli-Gur C, Onbasilar I, Atilla P, Genç R, Cakar N, Deliloğlu-Gürhan I and Bedir E: In vitro growth stimulatory and in vivo wound healing studies on cycloartane-type saponins of Astragalus genus. J Ethnopharmacol. 134:844–850. 2011. View Article : Google Scholar : PubMed/NCBI
15	Meng JJ, Li SP, Zhao FY, Tong Y, Mu DZ and Qu Y: Effect of telomerase activation on biological behavior of neural stem cells in hypoxic-ischemic rats. Zhongguo Dang Dai Er Ke Za Zhi. 19:229–36. 2017.(In Chinese). PubMed/NCBI
16	Yi Z and Gao W: Protective effects of cycloastragenol on focal cerebral ischemia reperfusion injury in rats. Journa Cheng Medical Collage. 1–188. 2015.
17	Gao W: Pfect of cycloastragenol on neuronal apoptosis and TERT expression after cerebral ischemia reperfusion in rats. Chin J Pathophysiology. 10:18582015.
18	Reichert S, Bize P, Arrive M, Zahn S, Massemin S and Criscuolo F: Experimental increase in telomere length leads to faster feather regeneration. Exp Gerontol. 52:36–38. 2014. View Article : Google Scholar : PubMed/NCBI
19	Wang S, Zhai C, Liu Q, Wang X, Ren Z, Zhang Y, Zhang Y, Wu Q, Sun S, Li S and Qiao Y: Cycloastragenol, a triterpene aglycone derived from Radix astragali, suppresses the accumulation of cytoplasmic lipid droplet in 3T3-L1 adipocytes. Biochem Biophysical Res Commun. 450:306–311. 2014. View Article : Google Scholar
20	Gu M, Zhang S, Zhao Y, Huang J, Wang Y, Li Y, Fan S, Yang L, Ji G, Tong Q and Huang C: Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling. Pharmacol Res. 121:22–32. 2017. View Article : Google Scholar : PubMed/NCBI
21	Cao Y, Li W, Wei L, Liu X, Li Z and He W: Anti-aging effect of cyclogreitol on D-galactose induced aging mice. Chin J Exp Tradit Med Formulae. 1–211. 2012.
22	Richter T and von Zglinicki T: A continuous correlation between oxidative stress and telomere shortening in fibroblasts. Exp Gerontol. 42:1039–1042. 2007. View Article : Google Scholar : PubMed/NCBI
23	Zhao Y, Li Q, Zhao W, Li J, Sun Y, Liu K, Liu B and Zhang N: Astragaloside IV and cycloastragenol are equally effective in inhibition of endoplasmic reticulum stress-associated TXNIP/NLRP3 inflammasome activation in the endothelium. J Ethnopharmacol. 169:210–218. 2015. View Article : Google Scholar : PubMed/NCBI
24	Sun C, Jiang M, Zhang L, Yang J, Zhang G, Du B, Ren Y, Li X and Yao J: Cycloastragenol mediates activation and proliferation suppression in concanavalin A-induced mouse lymphocyte pan-activation model. Immunopharmacol Immunotoxicol. 39:131–139. 2017. View Article : Google Scholar : PubMed/NCBI
25	Harley CB, Liu W, Blasco M, Vera E, Andrews WH, Briggs LA and Raffaele JM: A natural product telomerase activator as part of a health maintenance program. Rejuvenation Res. 14:45–56. 2011. View Article : Google Scholar : PubMed/NCBI
26	Harley CB, Liu W, Flom PL and Raffaele JM: A natural product telomerase activator as part of a health maintenance program: metabolic and cardiovascular response. Rejuvenation Res. 16:386–395. 2013. View Article : Google Scholar : PubMed/NCBI
27	Dow CT and Harley CB: Evaluation of an oral telomerase activator for early age-related macular degeneration-a pilot study. Clin Ophthalmol. 10:243–249. 2016. View Article : Google Scholar : PubMed/NCBI
28	Aschacher T, Wolf B, Enzmann F, Kienzl P, Messner B, Sampl S, Svoboda M, Mechtcheriakova D, Holzmann K and Bergmann M: LINE-1 induces hTERT and ensures telomere maintenance in tumour cell lines. Oncogene. 35:94–104. 2016. View Article : Google Scholar : PubMed/NCBI
29	Szabo NJ: Dietary safety of cycloastragenol from Astragalus spp: Subchronic toxicity and genotoxicity studies. Food Chem Toxicol. 64:322–334. 2014. View Article : Google Scholar : PubMed/NCBI
30	Ran R, Zhang C, Li R, Chen B, Zhang W, Zhao Z, Fu Z, Du Z, Du X, Yang X and Fang Z: Evaluation and comparison of the inhibition effect of astragaloside IV and aglycone cycloastragenol on various UDP-Glucuronosyltransferase (UGT) isoforms. Molecules. 21:E16162016. View Article : Google Scholar : PubMed/NCBI
31	T.A.: Sciences^®: TA-65^® Receives Generally Recognized as Safe Status. https://www.tasciences.com/ta-65-receives-generally-recognized-safe-status/November 19–2014
32	Shay JW and Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer. 33:787–791. 1997. View Article : Google Scholar : PubMed/NCBI
33	Zhu J, Lee S, Ho MK, Hu Y, Pang H, Ip FC, Chin AC, Harley CB, Ip NY and Wong YH: In vitro intestinal absorption and first-pass intestinal and hepatic metabolism of cycloastragenol, a potent small molecule telomerase activator. Drug Metab Pharmacokinet. 25:477–486. 2010. View Article : Google Scholar : PubMed/NCBI
34	Liu X: In vitro and in vivo metabolism research of astragaloside iv and cycloastragenol (unpublished PhD thesis). Beijing University of Chinese Medicine. 2013, PubMed/NCBI
35	Wei B, Ye J, Bi B, Sun G, Yang X and Zhang Y: Effect of continuous intragastric administration of cycloastragenol on liver p450 enzymes in rats. Chin J New Drugs. 1–479. 2014.